An Open Label, Parallel Group, Randomized Phase I Study of Biological Activity, Safety, Tolerability, and Clinical Activity of Different Dose Levels of EMD 640 744 in Montanide ISA 51 VG Administered in Subjects With Advanced Solid Tumors.

Trial Profile

An Open Label, Parallel Group, Randomized Phase I Study of Biological Activity, Safety, Tolerability, and Clinical Activity of Different Dose Levels of EMD 640 744 in Montanide ISA 51 VG Administered in Subjects With Advanced Solid Tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 18 Apr 2014

At a glance

  • Drugs EMD 640744 (Primary) ; Montanide ISA-51
  • Indications Solid tumours
  • Focus Pharmacodynamics
  • Sponsors Merck KGaA
  • Most Recent Events

    • 03 Oct 2011 Actual end date Sep 2011 added as reported by ClinicalTrials.gov.
    • 03 Oct 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 05 Aug 2010 Planned end date changed from 1 Oct 2010 to 1 Dec 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top